BBIO News and Press, BridgeBio Pharma Inc. From 01/14/26

2026-01-14 16:09:21 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Bri...

-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt maturity PALO ALTO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “...

2026-01-12 14:25:58 ET BridgeBio Pharma, Inc. (BBIO) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 10:30 AM EST... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Co...

2026-01-12 12:34:30 ET More on markets AllianceBernstein sees steady growth in 2026, but flags rising volatility and policy risks Cantor Fitzgerald sees tailwinds for 2026, but warns of a potential Q1 drawdown Goldman Sachs sees the bull market rolling on in 2026 a...

-  Preliminary unaudited Q4 and Full Year 2025 net Attruby ® product revenue of $146.0 million and $362.4 million, respectively - Attruby (acoramidis) is rapidly becoming the first-choice therapy for newly diagnosed ATTR-CM patients with 6,629 unique patient prescriptions writ...

2026-01-09 11:25:07 ET BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study January 9, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO) Di...

2026-01-08 08:05:37 ET from Truist Financial issued a price target of $86.00 for BBIO on 2026-01-08 12:53:20. The adjusted price target was set to $86.00. At the time of the announcement, BBIO was trading at $74.27. The overall price target consensus is at $88.22 with hi...

PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at t...

PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, January ...

2025-12-25 21:40:55 ET This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 11/14/2025. Please visit our ...